Phase 3 AURORA trial of Descartes-08 in myasthenia gravis (MG) advances towards data readout expected in 1Q27 and biologics license application (BLA) filing planned for mid-2027 Retreatment data for Descartes-08 in MG showed deep and durable responses, with a mean 6.6-point MG Activities of Daily Living (MG-ADL) reduction from baseline at Month 12 with no new safety signals Phase 2 TRITON trial of Descartes-08 in myositis and Phase 1/2 HELIOS pediatric trial of Descartes-08 in juvenile dermatomy
Detailed price information for Surgery Partners CS (SGRY-Q) from The Globe and Mail including charting and trades.
Detailed price information for Uniqure N.V. (QURE-Q) from The Globe and Mail including charting and trades.
FREDERICK, Md., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced the granting of inducement awards to three new employees. On September 4, 2026, the Company issued to these employees options to purchase an aggregate of 59,700 shares of the Company’s common stock with an exercise price of $9.27, the closing trading price of the Company’s commo
FREDERICK, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Cartesian Therapeutics, Inc. (NASDAQ: RNAC) (the “Company”), a late clinical-stage biotechnology company pioneering cell therapy for autoimmune diseases, today announced that its management expects to participate in the following investor conferences in September: A fireside chat at the 2026 Cantor Global Healthcare Conference at 3:55 p.m. ET on Thursday, September 10, 2026One-on-one and group investor meetings at Morgan Stanley’s 24th Annual He
This is the newest page. Registered accounts read further back.